Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 390.21 Million KRW | 688.68% |
| 2022 | 49.47 Million KRW | -41.57% |
| 2021 | 84.67 Million KRW | 141.93% |
| 2020 | 35 Million KRW | -30.61% |
| 2019 | 50.44 Million KRW | -98.32% |
| 2018 | 3 Billion KRW | 657.58% |
| 2017 | 396 Million KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | -100.0% |
| 2011 | 249.96 Million KRW | 0.0% |
| 2010 | - KRW | -100.0% |
| 2009 | 7.01 Billion KRW | 133.68% |
| 2008 | 3 Billion KRW | -87.85% |
| 2007 | 24.69 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 353.7 Million KRW | 0.0% |
| 2024 Q1 | 367.56 Million KRW | -100.0% |
| 2023 Q1 | 44.69 Million KRW | -9.67% |
| 2023 Q4 | 390.21 Million KRW | 360.56% |
| 2023 FY | 390.21 Million KRW | 688.68% |
| 2023 Q2 | 39.87 Million KRW | -10.79% |
| 2023 Q3 | 84.72 Million KRW | 112.51% |
| 2022 Q2 | 66.63 Million KRW | -11.96% |
| 2022 FY | 49.47 Million KRW | -41.57% |
| 2022 Q4 | 49.47 Million KRW | -22.35% |
| 2022 Q3 | 63.72 Million KRW | -4.37% |
| 2022 Q1 | 75.68 Million KRW | -10.62% |
| 2021 Q1 | 30.74 Million KRW | -12.17% |
| 2021 Q4 | 84.67 Million KRW | 25.44% |
| 2021 Q2 | 26.46 Million KRW | -13.92% |
| 2021 Q3 | 67.5 Million KRW | 155.08% |
| 2021 FY | 84.67 Million KRW | 141.93% |
| 2020 FY | 35 Million KRW | -30.61% |
| 2020 Q1 | 46.25 Million KRW | -8.3% |
| 2020 Q3 | 37.82 Million KRW | -10.05% |
| 2020 Q4 | 35 Million KRW | -7.47% |
| 2020 Q2 | 42.05 Million KRW | -9.09% |
| 2019 Q4 | 50.44 Million KRW | -98.35% |
| 2019 FY | 50.44 Million KRW | -98.32% |
| 2019 Q3 | 3.05 Billion KRW | -0.13% |
| 2019 Q2 | 3.05 Billion KRW | 1.89% |
| 2019 Q1 | 3 Billion KRW | 0.0% |
| 2018 Q4 | 3 Billion KRW | 0.0% |
| 2018 Q2 | 3 Billion KRW | 6.38% |
| 2018 FY | 3 Billion KRW | 657.58% |
| 2018 Q1 | 2.82 Billion KRW | 612.17% |
| 2018 Q3 | 3 Billion KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q4 | 396 Million KRW | 0.0% |
| 2017 FY | 396 Million KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2012 FY | - KRW | -100.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 Q1 | 208.3 Million KRW | 0.0% |
| 2011 Q3 | 751.62 Million KRW | 0.0% |
| 2011 Q2 | - KRW | 0.0% |
| 2011 Q1 | - KRW | 0.0% |
| 2011 FY | 249.96 Million KRW | 0.0% |
| 2010 Q1 | 7.04 Billion KRW | 0.48% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | - KRW | -100.0% |
| 2010 Q2 | - KRW | -100.0% |
| 2010 Q3 | 8.2 Billion KRW | 0.0% |
| 2009 Q3 | 6.97 Billion KRW | 132.57% |
| 2009 Q2 | 3 Billion KRW | 0.0% |
| 2009 Q1 | 3 Billion KRW | 0.0% |
| 2009 FY | 7.01 Billion KRW | 133.68% |
| 2009 Q4 | 7.01 Billion KRW | 0.48% |
| 2008 Q1 | 24.69 Billion KRW | 0.0% |
| 2008 Q4 | 3 Billion KRW | -84.37% |
| 2008 FY | 3 Billion KRW | -87.85% |
| 2008 Q2 | 24.69 Billion KRW | 0.0% |
| 2008 Q3 | 19.19 Billion KRW | -22.27% |
| 2007 FY | 24.69 Billion KRW | 0.0% |
| 2007 Q4 | 24.69 Billion KRW | 0.0% |
| 2007 Q3 | 24.69 Billion KRW | 0.0% |
| 2007 Q2 | 24.69 Billion KRW | 0.0% |
| 2007 Q1 | 24.69 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 2.43 Billion KRW | 83.985% |
| Green Cross Holdings Corporation | 216.35 Billion KRW | 99.82% |
| Green Cross Holdings Corporation | 84.89 Billion KRW | 99.54% |
| Green Cross Corporation | 84.89 Billion KRW | 99.54% |
| GeneOne Life Science, Inc. | 6.27 Billion KRW | 93.779% |
| Celltrion, Inc. | 99.13 Billion KRW | 99.606% |
| Samsung Biologics Co.,Ltd. | 377.39 Billion KRW | 99.897% |
| SK bioscience Co.,Ltd. | 12.43 Billion KRW | 96.862% |
| SK Biopharmaceuticals Co., Ltd. | 94.48 Billion KRW | 99.587% |
| Prestige BioPharma Limited | 40.87 Billion KRW | 99.045% |